{"id":9044,"date":"2022-06-14T12:06:31","date_gmt":"2022-06-14T10:06:31","guid":{"rendered":"https:\/\/retina.ch\/?post_type=aktuelles&p=9044"},"modified":"2022-06-22T15:39:13","modified_gmt":"2022-06-22T13:39:13","slug":"etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie","status":"publish","type":"aktuelles","link":"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/","title":{"rendered":"Etude sur la maladie de Stargardt : ALK-001 ralentit l’\u00e9volution de la maladie"},"content":{"rendered":"\n

Une \u00e9tape importante dans le traitement de la d\u00e9g\u00e9n\u00e9rescence maculaire juv\u00e9nile de Stargardt. Comme le montre l’\u00e9tude clinique \u00ab\u00a0Tolerability and effects of ALK-001 on Stargardt’s disease\u00a0\u00bb, un m\u00e9dicament \u00e0 base de vitamine A modifi\u00e9e ralentit la progression de la maladie.<\/p>\n\n\n\n

L’\u00e9tude TEASE (\u00ab\u00a0Tolerability and Effects of ALK-001 on Stargardt Disease\u00a0\u00bb), un essai clinique  multicentrique, \u00e0 double insu, randomis\u00e9 et contr\u00f4l\u00e9 par placebo, visait \u00e0 \u00e9valuer le produit ALK-001 chez des patients atteints de la maladie de Stargardt atrophique. L’\u00e9tude, qui a dur\u00e9 deux ans, a \u00e9t\u00e9 men\u00e9e dans sept centres de recherche aux \u00c9tats-Unis.<\/p>\n\n\n\n

Le m\u00e9dicament exp\u00e9rimental ALK-001, une vitamine A chimiquement modifi\u00e9e, doit \u00eatre pris quotidiennement sous forme de comprim\u00e9s. Selon les donn\u00e9es pr\u00e9sent\u00e9es par le professeur Henrik Scholl (Institut d’ophtalmologie mol\u00e9culaire et clinique de B\u00e2le IOB), le produit ALK-001 a ralenti le taux de croissance de l’atrophie r\u00e9tinienne, et par cons\u00e9quent de la zone endommag\u00e9e de la r\u00e9tine, d’environ 30 % en un an.<\/p>\n\n\n\n

Aux \u00c9tats-Unis, on d\u00e9nombre plus de 40 000 personnes atteintes de la maladie de Stargardt. En r\u00e8gle g\u00e9n\u00e9rale, la maladie se manifeste d\u00e8s l’adolescence. Jusqu’\u00e0 pr\u00e9sent, il n’existe aucune th\u00e9rapie reconnue, de sorte que la plupart des personnes concern\u00e9es deviennent aveugles \u00e0 l’\u00e2ge de 50 ans.<\/p>\n\n\n\n

La vitamine A est importante pour la vision et la sant\u00e9 de la r\u00e9tine. Cependant, la vitamine A produit \u00e9galement des d\u00e9chets toxiques qui se d\u00e9posent dans la r\u00e9tine. Chez les patients atteints de la maladie de Stargardt, les d\u00e9p\u00f4ts de vitamine A s’accumulent plus rapidement, l’atrophie r\u00e9tinienne s’\u00e9tend plus vite et la vision est alt\u00e9r\u00e9e.<\/p>\n\n\n\n

\u00c0 ce jour, l’\u00e9tude TEASE est la seule \u00e0 avoir d\u00e9montr\u00e9 des effets statistiquement et cliniquement significatifs sur la progression de la maladie de Stargardt.<\/p>\n\n\n\n

\u00ab\u00a0L’\u00e9tude a montr\u00e9 qu’ALK-001 ralentit la progression de la maladie \u00e0 un stade avanc\u00e9, un r\u00e9sultat que beaucoup pensaient pratiquement impensable\u00a0\u00bb, a d\u00e9clar\u00e9 le professeur Scholl. \u00ab\u00a0Un effet aussi positif chez les patients atteints de la maladie de Stargardt \u00e0 un stade avanc\u00e9 nous r\u00e9jouit. Nous attendons maintenant de voir l’effet du m\u00e9dicament aux stades plus pr\u00e9coces de la maladie de Stargardt, stades dans lesquels les r\u00e9sultats devraient \u00eatre encore meilleurs.\u00a0\u00bb<\/p>\n\n\n\n

ALK-001 est le seul m\u00e9dicament exp\u00e9rimental capable de ralentir la formation de d\u00e9p\u00f4ts de vitamine A sans provoquer d’effets secondaires tels que la c\u00e9cit\u00e9 nocturne. \u00ab\u00a0Ces r\u00e9sultats sont la premi\u00e8re preuve clinique que les d\u00e9p\u00f4ts de vitamine A, que nous \u00e9tudions depuis pr\u00e8s de 30 ans maintenant, contribuent \u00e0 la progression de la d\u00e9g\u00e9n\u00e9rescence r\u00e9tinienne\u00a0\u00bb, a d\u00e9clar\u00e9 le Dr Ilyas Washington, le scientifique \u00e0 l’origine de la cr\u00e9ation du m\u00e9dicament \u00e0 base de vitamine A modifi\u00e9e.<\/p>\n\n\n\n

Lien : ARVO-Abstract<\/a><\/p>\n\n\n\n

Source : Institut d’ophtalmologie<\/a> mol\u00e9culaire et clinique de B\u00e2le (IOB), 03.05.2022<\/p>\n\n\n\n

\n
<\/span><\/span>S'inscrire pour<\/span>une consultation<\/span><\/a><\/span>\n<\/div>\n\n\n\n
<\/span><\/span>Retina Suisse<\/span>Contact<\/span><\/a><\/span>\n<\/div>\n\n\n\n
<\/span><\/span>Adh\u00e9rer \u00e0<\/span>Retina Suisse<\/span><\/a><\/span>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Une \u00e9tape importante dans le traitement de la d\u00e9g\u00e9n\u00e9rescence maculaire juv\u00e9nile de Stargardt. Un m\u00e9dicament \u00e0 base de vitamine A modifi\u00e9e ralentit la progression de la maladie.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"_FSMCFIC_featured_image_caption":"","_FSMCFIC_featured_image_nocaption":"","_FSMCFIC_featured_image_hide":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[105,70],"class_list":["post-9044","aktuelles","type-aktuelles","status-publish","hentry","category-morbus-stargardt-fr","category-recherche"],"acf":[],"yoast_head":"\nEtude sur la maladie de Stargardt : ALK-001 ralentit l'\u00e9volution de la maladie • Retina Suisse<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Etude sur la maladie de Stargardt : ALK-001 ralentit l'\u00e9volution de la maladie • Retina Suisse\" \/>\n<meta property=\"og:description\" content=\"Une \u00e9tape importante dans le traitement de la d\u00e9g\u00e9n\u00e9rescence maculaire juv\u00e9nile de Stargardt. Un m\u00e9dicament \u00e0 base de vitamine A modifi\u00e9e ralentit la progression de la maladie.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/\" \/>\n<meta property=\"og:site_name\" content=\"Retina Suisse\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/retinasuisse\/\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-22T13:39:13+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/\",\"url\":\"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/\",\"name\":\"Etude sur la maladie de Stargardt : ALK-001 ralentit l'\u00e9volution de la maladie • Retina Suisse\",\"isPartOf\":{\"@id\":\"https:\/\/retina.ch\/fr\/#website\"},\"datePublished\":\"2022-06-14T10:06:31+00:00\",\"dateModified\":\"2022-06-22T13:39:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Retina Suisse\",\"item\":\"https:\/\/retina.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/retina.ch\/fr\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Etude sur la maladie de Stargardt : ALK-001 ralentit l’\u00e9volution de la maladie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/retina.ch\/fr\/#website\",\"url\":\"https:\/\/retina.ch\/fr\/\",\"name\":\"Retina Suisse\",\"description\":\"Retina Suisse ist die Vereinigung von Patientinnen und Patienten mit Retinitis pigmentosa (RP), Makuladegeneration, Usher-Syndrom und anderen Erkrankungen des Augenhintergrundes.\",\"publisher\":{\"@id\":\"https:\/\/retina.ch\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/retina.ch\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/retina.ch\/fr\/#organization\",\"name\":\"Retina Suisse\",\"url\":\"https:\/\/retina.ch\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/retina.ch\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/retina.ch\/wp-content\/uploads\/2020\/09\/retina-auge-typo.svg\",\"contentUrl\":\"https:\/\/retina.ch\/wp-content\/uploads\/2020\/09\/retina-auge-typo.svg\",\"width\":\"1024\",\"height\":\"1024\",\"caption\":\"Retina Suisse\"},\"image\":{\"@id\":\"https:\/\/retina.ch\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/retinasuisse\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Etude sur la maladie de Stargardt : ALK-001 ralentit l'\u00e9volution de la maladie • Retina Suisse","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/","og_locale":"fr_FR","og_type":"article","og_title":"Etude sur la maladie de Stargardt : ALK-001 ralentit l'\u00e9volution de la maladie • Retina Suisse","og_description":"Une \u00e9tape importante dans le traitement de la d\u00e9g\u00e9n\u00e9rescence maculaire juv\u00e9nile de Stargardt. Un m\u00e9dicament \u00e0 base de vitamine A modifi\u00e9e ralentit la progression de la maladie.","og_url":"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/","og_site_name":"Retina Suisse","article_publisher":"https:\/\/www.facebook.com\/retinasuisse\/","article_modified_time":"2022-06-22T13:39:13+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/","url":"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/","name":"Etude sur la maladie de Stargardt : ALK-001 ralentit l'\u00e9volution de la maladie • Retina Suisse","isPartOf":{"@id":"https:\/\/retina.ch\/fr\/#website"},"datePublished":"2022-06-14T10:06:31+00:00","dateModified":"2022-06-22T13:39:13+00:00","breadcrumb":{"@id":"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/retina.ch\/fr\/actualites\/etude-sur-la-maladie-de-stargardt-alk-001-ralentit-levolution-de-la-maladie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Retina Suisse","item":"https:\/\/retina.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9s","item":"https:\/\/retina.ch\/fr\/actualites\/"},{"@type":"ListItem","position":3,"name":"Etude sur la maladie de Stargardt : ALK-001 ralentit l’\u00e9volution de la maladie"}]},{"@type":"WebSite","@id":"https:\/\/retina.ch\/fr\/#website","url":"https:\/\/retina.ch\/fr\/","name":"Retina Suisse","description":"Retina Suisse ist die Vereinigung von Patientinnen und Patienten mit Retinitis pigmentosa (RP), Makuladegeneration, Usher-Syndrom und anderen Erkrankungen des Augenhintergrundes.","publisher":{"@id":"https:\/\/retina.ch\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/retina.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/retina.ch\/fr\/#organization","name":"Retina Suisse","url":"https:\/\/retina.ch\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/retina.ch\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/retina.ch\/wp-content\/uploads\/2020\/09\/retina-auge-typo.svg","contentUrl":"https:\/\/retina.ch\/wp-content\/uploads\/2020\/09\/retina-auge-typo.svg","width":"1024","height":"1024","caption":"Retina Suisse"},"image":{"@id":"https:\/\/retina.ch\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/retinasuisse\/"]}]}},"_links":{"self":[{"href":"https:\/\/retina.ch\/fr\/wp-json\/wp\/v2\/aktuelles\/9044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/retina.ch\/fr\/wp-json\/wp\/v2\/aktuelles"}],"about":[{"href":"https:\/\/retina.ch\/fr\/wp-json\/wp\/v2\/types\/aktuelles"}],"version-history":[{"count":4,"href":"https:\/\/retina.ch\/fr\/wp-json\/wp\/v2\/aktuelles\/9044\/revisions"}],"predecessor-version":[{"id":9515,"href":"https:\/\/retina.ch\/fr\/wp-json\/wp\/v2\/aktuelles\/9044\/revisions\/9515"}],"wp:attachment":[{"href":"https:\/\/retina.ch\/fr\/wp-json\/wp\/v2\/media?parent=9044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/retina.ch\/fr\/wp-json\/wp\/v2\/categories?post=9044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}